PALATIN TECHNOLOGIES (PTNT) Company Report

Palatin Technologies announced the pricing of an underwritten public offering, expected to generate approximately $15.8 million in gross proceeds, with the potential for an additional $15.8 million upon the cash exercise of milestone-related Series J Warrants.
The offering includes 2,430,769 shares of common stock (or pre-funded warrants) along with Series J and Series K warrants, at a combined public offering price of $6.50 per share.
The net proceeds from the offering are intended to support the development of the company's obesity program and for working capital and general corporate purposes.
The closing of the offering is expected to enable Palatin to regain compliance with NYSE American listing standards, with trading of its common stock anticipated to resume on November 12, 2025, under the symbol "PTN".

Nov 6, 2025, 12:30 PM

Palatin Technologies Announces Milestone Payment from Boehringer Ingelheim Collaboration

PTNT

New Projects/Investments

Revenue Acceleration/Inflection

Palatin Technologies, Inc. announced the achievement of a research milestone in its collaboration with Boehringer Ingelheim, resulting in a €5.5 million ($6.5 million) payment.
This collaboration, established on August 18, 2025, aims to develop melanocortin receptor-targeted treatments for diabetic retinopathy and diabetic macular edema.
Under the agreement, Palatin received an upfront payment of €2.0 million ($2.3 million) and is eligible for up to €18.0 million ($21.2 million) in near-term research milestones (including the current payment), and up to €260 million ($307 million) in success-based development, regulatory, and commercial milestone payments, plus tiered royalties on net sales.

Sep 22, 2025, 12:07 PM

Palatin Technologies receives milestone payment from Boehringer Ingelheim collaboration

PTNT

New Projects/Investments

Earnings

Palatin Technologies (PTNT) announced on September 22, 2025, the achievement of a research milestone under its collaboration with Boehringer Ingelheim.
This milestone triggered a payment of €5.5 million ($6.5 million) to Palatin.
The collaboration, which began on August 18, 2025, is focused on developing potential first-in-class melanocortin receptor-targeted treatments for patients with diabetic retinopathy, including diabetic macular edema.
Palatin is eligible for additional research, development, regulatory, and commercial milestone payments of up to €278 million ($328 million), as well as tiered royalties on net sales from this partnership.